High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: Time to rethink?

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 4, 2015, Pages 620-624

  Mohty, Mohamad ^a,b,c   Malard, Florent ^a,b,c   Savani, Bipin N ^d  

^a HÔPITAL SAINT ANTOINE   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; High dose total body irradiation; Long term complication; Myeloablative conditioning regimen; Nonrelapse mortality; Overall survival

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HUMAN; IATROGENIC DISEASE; IMMUNE DEFICIENCY; MALIGNANT NEOPLASTIC DISEASE; MYELOABLATIVE CONDITIONING; RADIATION DOSE; REVIEW; RISK; WHOLE BODY RADIATION; ALLOGRAFT; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PROCEDURES; SURVIVAL RATE;

ALLOGRAFTS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 84924285344     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.010     Document Type: Review

References (34)

1. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
2. Shankar S.M., Carter A., Sun C.L., et al. Health care utilization by adult long-term survivors of hematopoietic cell transplant: report from the Bone Marrow Transplant Survivor Study. Cancer Epidemiol Biomarkers Prev 2007, 16:834-839.
3. Malard F., Chevallier P., Guillaume T., et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution's three decade experience. Biol Blood Marrow Transplant 2014, 20:1217-1223.
4. Bhatia S., Francisco L., Carter A., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007, 110:3784-3792.
5. Sun C.L., Francisco L., Kawashima T., et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010, 116:3129-3139. quiz 3377.
6. Mohty B., Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 2011, 1:e16.
7. Socie G., Salooja N., Cohen A., et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003, 101:3373-3385.
8. Tichelli A., Rovo A., Passweg J., et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009, 2:583-601.
9. Mohty M., Apperley J.F. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematol Am Soc Hematol Educ Progr 2010, 2010:229-236.
10. Tichelli A., Gratwohl A., Egger T., et al. Cataract formation after bone marrow transplantation. Ann Intern Med 1993, 119:1175-1180.
11. Belkacemi Y., Labopin M., Vernant J.P., et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys 1998, 41:659-668.
12. Rovo A., Van Lint M.T., Aljurf M., et al. Spermatogenesis recovery in male survivors after HSCT: evidence for graft-versus-testis effect, on behalf of the Late Effects Working Party-EBMT. Bone Marrow Transplant 2010, 45(Suppl 2s). abstract 92.
13. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007, 109:1765-1772.
14. Kersting S., Hene R.J., Koomans H.A., Verdonck L.F. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1169-1175.
15. Choi M., Sun C.L., Kurian S., et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer 2008, 113:1580-1587.
16. Al-Hazzouri A., Cao Q., Burns L.J., et al. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:658-663.
17. Frisk P., Bratteby L.E., Carlson K., Lonnerholm G. Renal function after autologous bone marrow transplantation in children: a long-term prospective study. Bone Marrow Transplant 2002, 29:129-136.
18. Hingorani S., Guthrie K.A., Schoch G., et al. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 2007, 39:223-229.
19. Tichelli A., Bhatia S., Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008, 142:11-26.
20. Tichelli A., Bucher C., Rovo A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110:3463-3471.
21. Kolb H.J., Socie G., Duell T., et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999, 131:738-744.
22. Heilmeier B., Stowasser N., Socie G., et al. Malignant neoplasms in long-term survivors of bone marrow transplantation-follow up. ASH Annu Meet Abstr 2008, 112:453.
23. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
24. Majhail N.S., Brazauskas R., Rizzo J.D., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011, 117:316-322.
25. Friedman D.L., Rovo A., Leisenring W., et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008, 111:939-944.
26. Ringden O., Brazauskas R., Wang Z., et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced intensity conditioning. Biol Blood Marrow Transplant 2014.
27. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
28. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
29. Nagler A., Rocha V., Labopin M., et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen-a report from the acute leukemia working party of the European Group forBlood And Marrow Transplantation. JClin Oncol 2013, 31:3549-3556.
30. Copelan E.A., Hamilton B.K., Avalos B., et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013, 122:3863-3870.
31. Cheuk D.K. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant 2013, 3:99-112.
32. Duong H.K., Savani B.N., Copelan E., et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014.
33. Ten Brink M.H., Zwaveling J., Swen J.J., et al. Personalized busulfan andtreosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today 2014.
34. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 2012, 5:1-30.